Alimera Sciences, Inc. (NASDAQ:ALIM) Short Interest Down 13.8% in August

Alimera Sciences, Inc. (NASDAQ:ALIM) was the recipient of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 578,500 shares, a drop of 13.8% from the August 15th total of 670,900 shares. Based on an average daily trading volume, of 846,400 shares, the short-interest ratio is currently 0.7 days.

Hedge Funds Weigh In On Alimera Sciences

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Glazer Capital LLC acquired a new position in Alimera Sciences during the 2nd quarter valued at approximately $3,067,000. Ancora Advisors LLC purchased a new position in shares of Alimera Sciences in the first quarter worth $915,000. Renaissance Technologies LLC lifted its stake in shares of Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 6,900 shares during the period. Finally, Deltec Asset Management LLC acquired a new stake in shares of Alimera Sciences during the second quarter worth $690,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Stock Performance

Shares of ALIM stock opened at $5.54 on Wednesday. Alimera Sciences has a 12-month low of $2.61 and a 12-month high of $5.65. The business’s fifty day simple moving average is $5.56 and its 200-day simple moving average is $4.40. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80. The company has a market cap of $290.24 million, a PE ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The business had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Analysts expect that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALIM has been the topic of several recent research reports. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. StockNews.com assumed coverage on Alimera Sciences in a report on Saturday. They set a “hold” rating for the company. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research report on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).